{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-cell+Lymphomas+%28Phase+1%29&page=14", "query": { "condition": "B-cell Lymphomas (Phase 1)", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 1137, "total_pages": 114, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-cell+Lymphomas+%28Phase+1%29&page=15&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-cell+Lymphomas+%28Phase+1%29&page=13&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T19:10:31.787Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05024045", "title": "Study of Oral LOXO-338 in Patients With Advanced Blood Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia, Lymphocytic, Chronic, B-Cell", "Lymphoma, B-cell Marginal Zone", "Lymphoma, Non-Hodgkin", "Multiple Myeloma", "B-cell Lymphoma", "Waldenstrom Macroglobulinemia", "Lymphoma, Mantle-Cell" ], "interventions": [ { "name": "LOXO-338", "type": "DRUG" }, { "name": "Pirtobrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2021-09-30", "completion_date": "2026-03-02", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-14T19:10:31.787Z", "location_count": 13, "location_summary": "Tucson, Arizona • Duarte, California • San Francisco, California + 10 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05024045" }, { "nct_id": "NCT01860937", "title": "T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed B-Cell Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "leukapheresis or collection of PBMCs", "type": "PROCEDURE" }, { "name": "cyclophosphamide based chemotherapy regimens", "type": "DRUG" }, { "name": "modified T cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "26 Years", "sex": "ALL", "summary": "Up to 26 Years" }, "enrollment_count": 23, "start_date": "2013-05", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-06-08", "last_synced_at": "2026-10-14T19:10:31.787Z", "location_count": 2, "location_summary": "Boston, Massachusetts • New York, New York", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01860937" }, { "nct_id": "NCT05275504", "title": "Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-Cell Malignancies" ], "interventions": [ { "name": "TT-01488", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TransThera Sciences (Nanjing), Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2022-06", "completion_date": "2023-04", "has_results": false, "last_update_posted_date": "2022-06-09", "last_synced_at": "2026-10-14T19:10:31.787Z", "location_count": 2, "location_summary": "Canton, Ohio • Houston, Texas", "locations": [ { "city": "Canton", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05275504" }, { "nct_id": "NCT04739813", "title": "Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Non-Hodgkin Lymphoma", "Diffuse Large B-Cell Lymphoma", "Burkitt Lymphoma" ], "interventions": [ { "name": "obinutuzumab", "type": "BIOLOGICAL" }, { "name": "prednisone", "type": "DRUG" }, { "name": "Revlimid", "type": "DRUG" }, { "name": "Polatuzumab", "type": "BIOLOGICAL" }, { "name": "ibrutinib", "type": "DRUG" }, { "name": "venetoclax", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 34, "start_date": "2021-07-09", "completion_date": "2031-06-18", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-10-14T19:10:31.787Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04739813" }, { "nct_id": "NCT00697346", "title": "Study of MLN8237 in Participants With Advanced Hematological Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-cell Follicular Lymphoma", "B-cell Marginal Zone Lymphoma", "Diffuse Large B-cell Lymphoma", "B-cell Mantle Cell Lymphoma", "B-cell Small Lymphocytic Lymphoma", "B-Cell Chronic Lymphocytic Leukemia", "Multiple Myeloma", "Waldenstrom's Macroglobulinemia", "Noncutaneous Peripheral T-cell Lymphoma Not Otherwise Specified", "Angioimmunoblastic T-cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Enteropathy Associated T-cell Lymphoma", "NK Lymphoma" ], "interventions": [ { "name": "Alisertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2008-07-11", "completion_date": "2016-10-19", "has_results": true, "last_update_posted_date": "2019-05-31", "last_synced_at": "2026-10-14T19:10:31.787Z", "location_count": 10, "location_summary": "Scottsdale, Arizona • Lexington, Kentucky • Baltimore, Maryland + 7 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00697346" }, { "nct_id": "NCT00025129", "title": "VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Small Intestine Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "laromustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vion Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2001-03", "completion_date": "2004-05", "has_results": false, "last_update_posted_date": "2013-07-18", "last_synced_at": "2026-10-14T19:10:31.787Z", "location_count": 3, "location_summary": "Tucson, Arizona • New Haven, Connecticut • West Haven, Connecticut", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "West Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00025129" }, { "nct_id": "NCT02890758", "title": "Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Myelodysplastic Syndrome", "Acute Lymphoblastic Leukemia", "Chronic Myeloid Leukemia", "Chronic Lymphocytic Leukemia", "Non Hodgkin Lymphoma", "Hodgkin Lymphoma", "Myeloproliferative Syndromes", "Plasma Cell Myeloma", "Colon Carcinoma", "Adenocarcinoma of Rectum", "Soft Tissue Sarcoma", "Ewing's Sarcoma", "Rhabdomyosarcoma" ], "interventions": [ { "name": "Natural Killer (NK) Cells", "type": "BIOLOGICAL" }, { "name": "ALT803", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Brenda Cooper, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2018-05-22", "completion_date": "2023-02-17", "has_results": false, "last_update_posted_date": "2023-02-21", "last_synced_at": "2026-10-14T19:10:31.787Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02890758" }, { "nct_id": "NCT00036790", "title": "Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Chronic Myeloproliferative Disorders", "Colorectal Cancer", "Head and Neck Cancer", "Leukemia", "Lung Cancer", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic/Myeloproliferative Diseases", "Prostate Cancer", "Small Intestine Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "motexafin gadolinium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": null, "start_date": "2002-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2019-12-17", "last_synced_at": "2026-10-14T19:10:31.787Z", "location_count": 2, "location_summary": "Pittsburgh, Pennsylvania • Madison, Wisconsin", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00036790" }, { "nct_id": "NCT00734890", "title": "Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer", "Lymphoma", "Lymphoproliferative Disorder", "Small Intestine Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "vandetanib", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2008-03", "completion_date": "2011-02", "has_results": false, "last_update_posted_date": "2012-03-16", "last_synced_at": "2026-10-14T19:10:31.787Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00734890" }, { "nct_id": "NCT00003887", "title": "Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Chronic Myeloproliferative Disorders", "Gestational Trophoblastic Tumor", "Kidney Cancer", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Neuroblastoma", "Ovarian Cancer", "Sarcoma", "Testicular Germ Cell Tumor" ], "interventions": [ { "name": "peripheral blood lymphocyte therapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "70 Years", "sex": "ALL", "summary": "1 Year to 70 Years" }, "enrollment_count": null, "start_date": "1998-08", "completion_date": "2003-02", "has_results": false, "last_update_posted_date": "2011-11-30", "last_synced_at": "2026-10-14T19:10:31.787Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003887" } ] }